- | Sio Gene Therapies
The Making of a Gene Therapy for an Ultra-Rare Disease
While the since renamed company Sio Gene Therapies in-licensed one program in Parkinson’s disease, it also in-licensed a pair of gene therapy programs from the University of Massachusetts in GM1 gangliosidosis and Tay-Sachs/Sandhoff disease with the GM1 program being Sio’s lead candidate.
- | Celularity
The placenta: a limitless source of stem cells?
US biotech firm Celularity is a leader in cell therapy development, and is focused on harnessing the therapeutic potential of cells contained in the postpartum placenta. Having raised over $350 million since spinning out from pharma giant Celgene, today the company has multiple cell therapy candidates in both pre-clinical and clinical development, with indications including chronic degenerative diseases such as Crohn’s.
- | Cue Biopharma
Filling A Vaccine Void with Cue Biopharma’s Dan Passeri, J.D.
CUE Biopharma CEO Dan Passeri, J.D. joins us for a discussion on the development of the company’s Immuno-STAT platform for the selective targeting and alteration of T cells. Passeri shares the rationale behind his belief in the company’s immunotherapeutic approach, and how the CUE-100 series of candidates in its pipeline are being developed to address a scourge of HPV-related head, neck, and other cancers.
- | Vaxart
COVID-19 vaccines — minus the needle? Researchers working on capsules, nasal sprays
According to FasterCures, which is tracking 326 COVID-19 treatments and 252 vaccines, five companies are developing oral vaccines, and two — ImmunityBio and Vaxart — have progressed to Phase 1 clinical trials.
- | AltruBio
New name, new board, new focus: AltruBio relaunches with $63M series A
AltruBio would like to reintroduce itself. After shifting from oncology to immunology, swapping out the board and completing a name change, the biotech is relaunching with a $63 million series A funding round.
- | OSE Immunotherapeutics
New agonist MAb resolves chronic inflammation
A French study has demonstrated that the novel agonist anti-human ChemR23 monoclonal antibody (MAb) designated OSE-230 accelerated recovery from acute inflammation and triggered resolution of chronic inflammation in mice chronic colitis models, preventing fibrosis and reducing tumor development.
- | Rezolute
mAb Manufacturing with Rezolute Bio’s Nevan Charles Elam, J.D.
Nevan Charles Elam, JD founded Rezolute Bio ten years ago on the heels of a complex career intersecting law, high tech, and life sciences. On this episode of the Business of Biotech, Elam shares the company’s rationale for pursuing congenital hyperinsulinism and diabetic macular edema therapeutics by leveraging monoclonal antibodies and discusses the company’s approach to process development and manufacturing.
- | Vaxart
Scientists Race To Develop Next Generation Of COVID Vaccines
“We wanted to develop a platform technology where we could easily give a vaccine, and obviously the easiest format to give would be a tablet,” says Sean Tucker, chief scientific officer at Vaxart.
